Expansion of peripheral and intratumoral regulatory T-cells in hepatocellular carcinoma: A case-control study

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 3, 2011, Pages 448-453

  Thakur, Sapna ^a   Singla, Anuj ^a   Chawla, Yogesh ^a   Rajwanshi, Arvind ^a   Kalra, Naveen ^a   Arora, Sunil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CTLA 4; FOXP3; hepatocellular carcinoma; immuneregulation; T regulatory cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CD4+ CD25+ T LYMPHOCYTE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DONOR; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LYMPHOCYTE SUBPOPULATION; MALE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TISSUE SECTION; TUMOR MICROENVIRONMENT;

ADULT; ANTIGENS, CD4; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 80053925077     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.85073     Document Type: Article

References (32)

1. Lopez LJ, Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2004;20:248-53.
2. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast. Liver Int 2005;25:696-703.
3. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T Cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-64.
4. Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-49.
5. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-11.
6. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.
7. Palmer DH, Hussain SA, Johnson PJ. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther 2005;5:507-23.
8. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27:407-14.
9. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase-mediated degradation of T-cell receptor-chain. Cancer Res 1999;59:1422-7.
10. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Andersson B, et al. Decreased expression of signal-transducing chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996;2:1825-8.
11. Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, et al. Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-KB activation. J Immunol 2001;167:2595-6.
12. Sakaguchi S. Regulatory T cells: Key controllers of immunologic selftolerance. Cell 2000;101:455-8.
13. Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2:827-34.
14. Hori S, Sakaguchi S. Foxp3: A critical regulator of the development and function of regulatory T cells. Microb Infect 2004;6:745-51.
15. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4 + CD25 + regulatory T cells in a colorectal carcinoma patients is mediated by transforming growth factor. Cancer Res 2002;62:5267-72.
16. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies. Possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99.
17. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
18. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4 + CD25 + T cells in tumors from patients with earlystage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
19. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
21. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of Regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
22. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, et al. Increase of CD4 + CD25 + regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006;45:254-62.
23. Boyer O, Saadoun D, Abriol J, Dodille M, Piette JC, Cacoub P, et al. CD4+ CD25+ regulatory T cells deficiency in patients with hepatitis C - mixed cryoglobulinemia vasculitis. Blood 2004;103:3428-30.
24. Boettler T, Spangenberg HC, Newman-Haeselin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T Cells during chronic hepatitis C virus infection. J Virol 2005;17:7860-7.
25. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 Expressing CD4+ CD25 + high regulatory T cells are over represented In human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
26. Sarween N, Chodos A, Raykundalia C, Khan M, Abbas AK, Walker LS. CD4+ CD25+ cells controlling a pathogenic CD4+ response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004;173:2942-51.
27. Gupta S, Joshi K, Vig JD, Arora SK. Intratumoral FoxP3expression in infiltrating breast carcinoma: Its association with clinicopathological parameters and angiogenesis. Acta Oncol 2007;46:792-7.
28. Longhi MS, Hussain MJ, Arora SK, Mieli-Vergani G, Vergani D, Ma Y: Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176:4484-91.
29. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD4+ CD25+ T Cells: A common basis between tumor immunity and auto immunity. J Immunol 1999;163:5211-8.
30. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii. Increased populations of regulatory T cells in peripheral blood and tumorinfiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
31. Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006;118:1-9.
32. Sutmuller RP, Duivenvoorde LM, Elsas AV, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of CTLA-4 blockade and depletion of CD25+ in anti tumor therapy reveals alternative pathway for suppression of auto reactive cyto toxic t lymphocyte responses. J Exp Med 2001;194:823-32.